Naomi Balzer Haas
Abramson Cancer Center · 638 works · 14,850 citations · h-index 55
Top works
- Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
- Akt-Dependent Metabolic Reprogramming Regulates Tumor Cell Histone Acetylation
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
- Radiation and immunotherapy: a synergistic combination
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer
- PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
- Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.